Safe Work Procedure for Preparation of Parenteral Hazardous Drugs

Site Applicability

All Providence Health Care sites, including acute, long term care, and ambulatory care areas, where hazardous drugs are prepared outside of pharmacy.

Practice Level

Basic:

• All clinicians with medication preparation and administration within their scope.

Requirements

A risk assessment (Appendix A) must be in place for this Safe Work Procedure to be followed.

Need to Know

- The final dosage form of a drug is a unit-dose packaged drug, ready to be administered to the patient without any preparation by the clinician.
- Preparation is any action taken to alter a drug product by means other than compounding or repackaging.
- When a hazardous drug is provided in the final dosage form the clinician is to follow the
 precautions outlined in the Control Matrix of the Exposure Control Program (<u>Appendix B</u>) for
 administration.
- This document outlines the steps to follow when preparation of the hazardous drug is required outside of pharmacy.
- Based upon a point of care risk assessment, conduct preparation in a low traffic area such as a medication room, alcove, or the patient's room as appropriate.
- All areas where hazardous drugs are stored, prepared or administered must have a Cytotoxic Spill Kit available

Equipment and Supplies

- Accelerated hydrogen peroxide wipes (i.e. Accel Intervention)
- Syringe
- Needle with filter (for ampoule)
- Needle (for vials)
- Plastic backed pad
- PPE:

This material has been prepared solely for use at Providence Health Care (PHC). PHC accepts no responsibility for use of this material by any person or organization not associated with PHC. A printed copy of this document may not reflect the current electronic version.

Effective date: 29/MAR/2023 Page 1 of 10

- Two pairs of chemo-approved gloves
- o Chemo-approved gown
- Eye and face protection (i.e. medical mask, and full face shield, or goggles)

Procedure

Work Surface Preparation:

1. For all procedures below, place plastic backed pad on surface on which the hazardous drug will be prepared.

Withdrawing from a vial (no dilution or reconstitution required):

- 1. Remove cap from the drug vial(s).
- 2. Scrub/clean septum (silicone/rubber seal) with alcohol swab, allow to dry.
- 3. Insert needle and inject air (same volume to be removed) into medication vial.
- 4. Withdraw correct medication dose into syringe.

Withdrawing from an ampoule:

- 1. Ensure that all medication is collected in the bottom of the ampoule (i.e. no liquid remaining in ampoule tip and neck).
- 2. Follow local procedures if using an ampoule breaking device.
- 3. If not using an ampoule breaking device, open and place a sterile alcohol swab package over ampoule tip and neck to minimize risk of splatter on opening.
- 4. If a scored point is on the ampoule, take care to turn scored point away from you and break ampoule on scored line by pulling tip towards you to snap off.
- 5. Use a filtered needle to withdraw medication from ampoule.
- 6. Change needle and discard filtered needle and ampoule body and tip in hazardous waste sharps (Group 1) or regular sharps container (Group 2).



Reconstituting medication in a vial:


- 1. Attach an unfiltered blunt fill needle to the syringe.
- 2. Remove cap from both the drug vial, and diluent vials if using.
- 3. Scrub/clean vial septum/s (silicone/rubber seal) with alcohol swab, allow to dry.
- 4. Inject air into the diluent vial equal to the volume to be withdrawn (not required if using a polyampule).
- 5. Withdraw the required volume of diluent.
- 6. Inject the diluent into the medication vial.

This material has been prepared solely for use at Providence Health Care (PHC). PHC accepts no responsibility for use of this material by any person or organization not associated with PHC. A printed copy of this document may not reflect the current electronic version.

Effective date: 29/MAR/2023 Page 2 of 10



7. Equalize vial pressure before removing the needle from the vial by withdrawing an equal amount of air to the diluent added from the 'air portion of the vial' into the empty diluent syringe (See Figure 1 below).



- 8. Mix the medication and diluent per drug specific instructions (i.e. PDTM, manufacturer's instructions).
- 9. Insert needle and inject air (same volume to be removed) into medication vial, withdraw correct dose into syringe.
- 10. Refer to Diluting section below if dilution in an IV bag is required.

Diluting:

- 1. In an IV bag (e.g. minibag):
 - a. Wipe minibag port with an alcohol swab.
 - b. Slowly inject hazardous drug into the minibag.
 - c. Remove the needle from the minibag port.
 - d. Dispose of needle and syringe as one unit.
 - e. Wipe the minibag port again with an alcohol swab to physically remove residual contamination.
 - f. Apply a hazardous drug auxiliary label in addition to the regular medication label.
 - g. Ensure that IV lines are primed with a compatible IV solution prior to attaching minibag.
 - WARNING: Do NOT prime lines with hazardous drugs.

Labelling:

1. In addition to standard labelling requirements, apply a Hazardous Drugs Group 1 or Hazardous Drugs Group 2 label to prepared syringes and IV bags.

Work Surface Cleaning

1. After each procedure above the work surface must be cleaned and decontaminated using a two-step process using accelerated hydrogen peroxide wipes (i.e. Accel Intervention).

This material has been prepared solely for use at Providence Health Care (PHC). PHC accepts no responsibility for use of this material by any person or organization not associated with PHC. A printed copy of this document may not reflect the current electronic version.

Effective date: 29/MAR/2023 Page 3 of 10

Related Documents

- Diluting Medications for Parenteral Administration
- Low Level Cleaning and Disinfection (Infection Control)

References

Adapted from provincial Safe Work Procedure Hazardous Drugs Safe Work Procedure: IV IM IP and SC Parenteral Administration in Care Settings

Appendices

- Appendix A: Risk Assessment
- Appendix B: Providence Health Care Hazardous Drug Control Matrix

Effective date: 29/MAR/2023 Page 4 of 10

Appendix A: Risk Assessment

A. Detailed Risk Assessment

Site:	All PHC acute, long term, and ambulatory sites	Unit:	Generic template
Date of assessment:	02-FEB-2022	Next review date (1 year)	02-FEB-2022
Name of Drug:		Drug Group (1 or 2)	Group 1 or 2
Route of Administration:	IM, IV, SC	Formulation:	Parenteral

	Name of Drug:		Drug Group (1 or 2)	Group 1 or 2
	Route of Administration:	IM, IV, SC	Formulation:	Parenteral
1	☑ Biological s available☑ Pharmacy s☑ Transporta	unable to provide final dos afety cabinet (BSC)/ Conta staff are not available (e.g. tion limitations/restriction	inment – Primary Enginee qualifications, outside of o	ring Control (C-PEC) not
		drug I urgency (i.e. urgent need	for drug administration)	
2	a) Reconstitu b) Withdrawa	n from standard practice (uted al (partial or full) . mini-bag or syringe)	e.g. drug will be crushed, n	nixed, combined etc.):
3	control measures i ☑ Absorption ☐ Inhalation	•	·	·
4	. Based on the type contamination? ☑ Yes ☐ No	of preparation and/or for	mulation, is there a risk of	environmental

This material has been prepared solely for use at Providence Health Care (PHC). PHC accepts no responsibility for use of this material by any person or organization not associated with PHC. A printed copy of this document may not reflect the current electronic version.

Effective date: 29/MAR/2023 Page 5 of 10



Proposed Engineering Control(s):

B. Alternate Control Measures for Development of Safe Work Procedures

Use the list below to identify control measures for the development of Safe Work Procedures (SWP) or reviewing an existing Safe Work Procedure for applicability. Note that when identifying control measures, **the hierarchy of controls must be considered**. In this process, engineering controls must be considered prior to or, in addition to, personal protective equipment (PPE).

The following lists can help to identify control options. Check all that applies and provide details in the SWP on how the control measures are utilized to prevent exposure. Refer to the Exposure Control Plan: Managing the Risks.

	roposed Engineering control(s).
	☐ Closed System Transfer Device
	☐ Filtered Venting Device
	☐ Pill crusher (enclosed system)
	☐ Pill dissolver (enclosed system)
	☐ Pill cutter (enclosed system)
	☐ Other (describe):
	⋈ None. No engineering controls are appropriate for alternate practice.
2.	Proposed Administrative Control(s):
	oxtimes Education on the safe preparation technique and equipment (e.g. filtered venting device
	oxtimes Identification of a location(s) for preparation which minimizes the number of individuals
	(staff, patients etc.) potentially exposed to hazardous drugs.
	oxtimes Methods used for minimizing surface contamination identified (e.g. using dedicated
	equipment, put an absorbent pad down)
	☑ Products and processes are in place for cleaning space post-preparation
	☑ Drug transportation and storage practices identified
	oxtimes Hazardous Drugs Spill kit is available and staff are trained on how to use it.
3.	Required PPE (refer to ECP Control Matrix, Decision Support Tools, and consider all potential
	routes of exposure):
	□ Chemo-approved gloves (two pairs)
	□ Chemo-approved gown
	□ Eye/face protection
	☐ Respiratory protection
	☐ Other (describe):

Effective date: 29/MAR/2023 Page 6 of 10

C. Safe Work Procedure

A Safe Work Procedure must be written considering all of the factors identified in both the **A. Detailed Risk Assessment** and **B. Alternative Control Measures** sections above. The SWP must be approved as per this risk assessment process prior to the administration of the drug.

Recommendation for SWP:

☑ Utilize a standardized Safe Work Procedure, all components are achievable.
☐ Modify an existing standardized Safe Work Procedure.
☐ Develop a unit or area based Safe Work Procedure.
\square No appropriate alternate practices or SWP can be identified, consult with your Health
Authority Hazardous Drugs Working Group.

Risk Assessment and Safe Work Procedure Developed By:					
Occupational Health and Safety	pational Health and Safety Hygienist, Occupational Health and Safety				
Pharmacy	Pharmacy Coordinator				
Professional Practice and Nursing	Practice Consultant				
Risk Assessment and Safe Work Procedure Endorsed By:					
Clinical Operations	Executive Director Acute Care				
	Program Director Seniors Care				
Occupational Health and Safety Director, Occupational Health and Safety					
Professional Practice and Nursing	Director, Professional Practice and Nursing				
Pharmacy	Director, Pharmacy (Acute Care)				
	Director, Pharmacy (Long Term Care)				

This material has been prepared solely for use at Providence Health Care (PHC). PHC accepts no responsibility for use of this material by any person or organization not associated with PHC. A printed copy of this document may not reflect the current electronic version.

Effective date: 29/MAR/2023 Page 7 of 10

Appendix B: Providence Health Care Hazardous Drug Control Matrix

PROVIDENCE HEALTH CARE - HAZARDOUS DRUGS CONTROL MATRIX

			PROVIDEN	CE HEALTH CARE - F	IAZARDOUS DRUGS CO	•			
BC Hazardous Drug Control Matrix			Group 1 🚠						
Nursing Section		Parenteral (IV, IVe, IM, SUBCUT, IT, IP)	Oral Solid (Tablet, Capsule)	Oral Liquid	Topical, Rectal & Vaginal	Implants and Ophthalmic		Inhalation Therapy	
LABELLING MEDICATION			Tension Heardown Drug						
			Do not use tube system		Do not use tube system	Do not use tube system	if liquid		
TRANSPORT IN FACILITY			If transporting drugs in a reusable outer container - two pairs of chemo-approved gloves are required If transporting drugs in a disposable outer container (e.g. plastic bag), PPE is not required Ensure a Hazardous Drugs spill kit accompanies drug transport or is readily available						
PREPARATION OF DRUGS BY NURSING			See Safe Work Procedures	3					
PRIMING	IV LINES		 Do not prime IV lines v 						
MEDICATION ADMINISTRATION		Gloves	two pairs of chemo- approved gloves	one pair of chemo-approved gloves	two pairs of chemo-approved	gloves			
Drugs in final dosage	PPE	Gown	chemo-approved gown	None	chemo-approved gown if risk				chemo-approved gown
form (including when		Eye/Face	eye/face protection	None	eye/face protection if risk of sp	olash			eye protection
using CSTDs)		N95	None						N95 Required
WORK SURFAC	CE CLEAN	NING		mo-approved gloves, chemo-g ogen Peroxide 0.5% (e.g. Acc	own, eye/face protection if risk of	fsplash			
PRECAUTIONARY PERIOD Place precautionary signage at the bedside or entrance to client room			The precautionary period is 48 hours following each administration of a Group 1 HD • During precautionary period • Required PPE: two pairs of chemo-approved gloves, chemo-approved gown, eyelface protection if risk of splash for any activities for which there is a risk of contact with BBF • Outside precautionary period • Follow routine precautions when handling blood and body fluids						
LABORATORY			During an individual's precautionary period all blood, urine and stool samples; other body fluids visibly contaminated with blood (except swabs and sputum) and tissues or organs not in fixatives must be labelled with a laboratory HD1 label All laboratory specimens from a patient in the precautionary period are to be placed in an outer sealed plastic bag. Blood specimens may be tubed, and must be labelled and placed in two sealed bags, with the outer bag labelled						
LAUNDRY			During precautionary period: All linen to be placed in Group 1 HD labelled laundry bag Required PPE: two pairs of chemo-approved gloves, chemo-approved gown, eye/face protection if risk of splash Outside precautionary period: All linen to be placed in regular laundry bag Required PPE: Follow routine practices						
			Drug V	Vaste	Sharps	BBF V			te (e.g. PPE and packaging)
SPILL MANAGEMENT Hazardous drug spill kits in all areas where hazardous drugs are handled			Intact solid dosage form Required PPE: one pair of cl All other dosage forms: Manage spills according to H	Hazardous Drug Spill	Manage spills according to Hazardous Drug Spill Cleanup Procedures for size of spill. See Appendix L in ECP s				
		Procedures for size of spill.	See Appendix L in ECP	Outstands Observe Ossets's	140	E	O de de de control	-4-1	
WASTE MANAGEMENT		ІТ	Controlled Substances: Pharmaceutical Waste Bin Non-Controlled Substance Cytotoxic Waste Bin	es:	Cytotoxic Sharps Container	Where possible, of through the sewer disposed of through leak-proof cytotox	r. Where not gh sewer, use a	Cytotoxic co	ntainer
Acute/Long Term Care (i.e., in facility) Acronyms: CSTD = Closed System Transfer Device			Required PPE: two pairs of chemo-app chemo-approved gowr eye/face protection if ri	n if risk of splash isk of splash	ar SUBCUT = Subcutaneous IT				

Acronyms: CSTD = Closed System Transfer Device | IV = Intravenous | IV

This material has been prepared solely for use at Providence Health Care (PHC). PHC accepts no responsibility for use of this material by any person or organization not associated with PHC. A printed copy of this document may not reflect the current electronic version.

Effective date: 29/MAR/2023 Page 8 of 10

PROVIDENCE HEALTH CARE - HAZARDOUS DRUGS CONTROL MATRIX

BC Hazardous Drug Con Nursing Section	ntrol Matr	ix	Group 2						
Nursing Section			Parenteral (IV, IVe, IM, SUBCUT, IT, IP)	Oral Solid (Tablet, Capsule)	Oral Liquid	Topical, Rectal & Vaginal	Implants and Ophthalmic		Inhalation Therapy
LABELLING MEDICATION	ON			Precautions Required GROU		HD	2		
			Do not use tube system		Do not use tube system Do not use tube system if liquid				
TRANSPORT IN FACILI	TY		 If transporting drugs i 	in a disposable outer containe	 two pairs of chemo-approved g (e.g. plastic bag), PPE is not r rug transport or is readily availal 	equired			
PREPARATION OF DRUGS BY NURSING		ONAL ECTIVE PMENT	See Safe Work Procedure	es					
PRIMING I	1 - 7		Do not prime IV lines	with hazardous drugs					
MEDICATION		Gloves	two pairs of chemo- approved gloves	one pair of chemo- approved gloves	two pairs of chemo-approved	gloves			
ADMINISTRATION Drugs in final dosage	PPE	Gown	chemo-approved gown	None	chemo-approved gown if risk of		None None		Chemo approved gown
form (including when using CSTDs)		Eye/Face	eye/face protection if risk of splash	None	eye protection if risk of splash	eye protection if risk of splash			eye protection
using COTES)		N95	None			N95 required			
WORK SURFAC			Wear two pairs of chemo-approved gloves, chemo-gown, eye/face protection if risk of splash Use Accelerated Hydrogen Peroxide 0.5% (e.g. Accel Intervention wipes™)						
PRECAUTIONA	ARY PER	IOD	Not applicable to Group 2 HD						
LABORA	TORY		Use routine practices for collection, labelling and transport						
LAUNE	DRY		 All linen to be placed 	All linen to be placed in regular laundry bags					
				Waste	Sharps		BBF Waste	Other Waste (e.g. PPE and packaging)
SPILL MANA	GEMEN	Т	Intact solid dosage form Required PPE: one pair of	chemo-approved gloves	Follow routine precaution	ons			
Hazardous drug spill kits in all areas where hazardous drugs are handled			All other dosage forms: Manage spills according to Procedures for size of spill.						
		Controlled Substances: Pharmaceutical Waste Bin		Regular Sharps Container	through dispose	possible, disposed of h the sewer. Where not ed of through sewer gular garbage or	Regular garb	age	
WASTE MANAGEMENT		Non-Controlled Substances:				nical or biohazardous			
Acute/Long Term Care (i.e., in facility)		Cytotoxic Waste Bin Required PPE: one pair of chemo-approved gloves		Follow routine practices	waste per usual practices. Follow routine practices and standard procedures				
			chemo-approved gown eye/face protection if ris	•					

Acronyms: CSTD = Closed System Transfer Device | IV = Intravenous | IV

Effective date: 29/MAR/2023 Page 9 of 10

5	STANDARD	OPERATING	PROCEDURE

First Released Date:	02-FEB-2022			
Posted Date:	29-MAR-2023			
Last Revised:	29-MAR-2023			
Last Reviewed:	29-MAR-2023			
Approved By:	PHC			
	Executive Director Acute Care, Clinical Informatics			
	Program Director Seniors Care			
	Director, Occupational Health and Safety			
	Director, Professional Practice and Nursing			
	Director, Pharmacy (Acute Care)			
	Director, Pharmacy (Long Term Care)			
Owners:	PHC			
	Occupational Health and Safety			

Effective date: 29/MAR/2023 Page 10 of 10